Redeye shares its initial thoughts on Urb-it’s Q4 report, where sales was SEK0.
Boreo reported Q4 adjusted EBIT ex-PPA of EUR 2.5m, 10% above our estimate (no consensus).
Redeye returns with a research update following Herantis H2 report.
Sales of SEK 14.3m vs ABGSCe 14.0m EBIT of SEK -35.
EcoRub tillkännagav den 2 mars att bolaget lanserar en ny produktserie riktad till hästägare under v...
41% org. growth and 4.7% EBITA, but some adjustments are due We increase ests.
Receives record DKK +2bn PPP order. Boosts an already high order book Another quality stamp for MTHH...
Redeye provides a research update following Infracom’s recent acquisitions of Connect and Datatal.
IRLAB Therapeutics has reported its full-year results for 2022, providing both a financial and an op...
Det avslutande kvartalet för år 2022 är presenterat och vi kan konstatera att det har varit ett utma...
Arbetsbrist och höga sjukskrivningstal tynger kvartalet… Drivet av förvärv ökade omsättningen med 14...
Förväntat lägre marginal under sista kvartalet Kvartalet var i stort sett som vi förväntat oss med e...
Redeye comments on SDS's recent announcement of progress made in its discussions with bondholders an...
Relais reported Q4 adjusted EBITA of EUR 7.9m, 8% below consensus and 9% below our estimate.
After entering three new markets in 2022, STENOCARE delivered products to a total of five countries ...
Överraskande stark tillväxt under Q4 men inför 2023 bedömer Analysguiden att det finns ett finansier...
Redeye provides an update following Heliospectra’s amended Q4'22 report, in which order intake was s...
Redeye updates on W5 following its Q4-results which saw solid growth but lower profitability than ex...
Redeye retains its positive view on Efecte, following a Q4 report with high growth from new sales, b...
Redeye lowers its long-term estimates and fair value range on the back of the Q4 2022 report.
